Skip to content

CMTA Press Room

Official News From Charcot-Marie-Tooth Association

CMTA’s Press Room Is Where We Share News That Shapes Not Only the Future of CMT Research but Real Impact Today. From Funding Announcements to Trial Updates, This Is Where Progress Moves From Idea to Action.


  • CMTA Fuels Breakthrough Imaging Research to Address CMT2A’s Cellular Weakness

    CMTA-Sponsored Research to Address CMT2A’s Cellular Weakness

    CMTA announced a $90,860 CMTA-STAR investment supporting advanced imaging research to examine how MFN2 mutations…

  • CMTA Invests $423K in Transformative Genomic Research to Advance CMT Diagnostics

    Solving CMT: CMTA Invests $423K in Gene Discovery

    CMTA is investing $423,000 in advanced genomic research to close diagnostic gaps in CMT and…

  • CMTA and INC Forge Groundbreaking Alliance to Accelerate Comprehensive Research Across All Charcot-Marie-Tooth Disease Types

    CMTA and INC Forge New Alliance

    What happens when the world’s largest CMT funder joins forces with the leading clinical research…

  • The Charcot-Marie-Tooth Association Appoints David Skarinsky to its Therapy Expert Board

    CMTA Appoints David Skarinsky to Therapy Expert Board

    CMTA announced the appointment of David Skarinsky to its CMTA-STAR Therapy Expert Board, adding deep…

  • CMTA’s $240K Investment Targets Gene Replacement Therapy in CMT4 Subtypes

    CMTA Invests $240K in Gene Replacement Research for CMT4

    CMTA announced a $240,000 investment AAV-based gene replacement for CMT4A, with potential implications for CMT4B1…

  • CMTA Appoints Science and Technology Veteran, Patricia Verduin, PhD, to the Board of Directors

    CMTA Appoints Patricia Verduin, PhD, to Board of Directors

    CMTA announced the appointment of Patricia Verduin, PhD, to its Board of Directors, adding science…

  • CMTA Announces Addition of Health Insurance Industry Veteran Wendy Arnone to the Board of Directors

    CMTA Appoints Wendy Arnone to Board of Directors

    CMTA announced the appointment of Wendy Arnone to its Board of Directors, adding healthcare executive…

  • CMTA’s $450K Investment Targets New Approach to Treatment for Patients with CMT1A and CMT1B

    CMTA Invests $450K in Research for CMT1A and CMT1B

    CMTA announced a $450,000 investment supporting research into a cGMP-based therapeutic approach for CMT1A and…

  • CMTA Board Evolution: Welcoming Bernard Coulie and Kevin Marks

    CMTA Welcomes Bernard Coulie and Kevin Marks to Board of Directors

    CMTA announced the appointment of Bernard Coulie, MD, PhD, and Kevin Marks to its Board…

  • Leading the Way: The CMTA Invests More Than $200K in Cutting-Edge CMT1A Organoid Research

    CMTA Invests Over $200K in CMT1A Models

    CMTA announced an investment of more than $200,000 to support CMT1A organoid research, establishing standardized…

  • The CMTA Appoints Professor Charlotte Sumner, M.D., to its Scientific Advisory Board

    CMTA Appoints Charlotte Sumner, MD, to Scientific Advisory Board

    CMTA announced the appointment of Charlotte Sumner, MD, to its Scientific Advisory Board, adding clinical…

  • CMTA Awards Over Half a Million Dollars to Fuel Research in Demyelinating Forms of CMT

    CMTA Awards Over $500K in New Research for Demyelinating Forms of CMT

    CMTA announced an investment of over $500,000 supporting international research projects focused on demyelinating forms…

Want the latest CMT research, news, and community updates delivered to your inbox?

Sign up for CMTA’s eNews and stay connected with the latest in CMT and CMTA news and events.

Your Pathway Doesn’t End Here. Your Journey Continues.

Where to Next?